



Symbio Pharmaceuticals Limited
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

December 26, 2008

Symbio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director, President and Chief Executive Officer

First Patient In for SyB L-0501 Phase I Trial to Treat Patients with Aggressive Non-Hodgkin's Lymphoma (NHL).

Symbio Pharmaceuticals Ltd. entered its first patient in the SyB L-0501 Phase I trial for the treatment of patients with relapsed aggressive NHL in combination with Rituximab in early December. This trial is being conducted at four facilities in accordance with the license agreement signed with Eisai Co., Ltd., and is two months ahead of schedule. Concurrently, the Phase II trial treating indolent NHL patients is ongoing and also ahead of schedule due to an unexpectedly high rate of enrollment and earlier than expected enrollment completion date. This accelerated pace of clinical trials in Japan will quickly advance the development of bendamustine in the area of hematology.

Bendamustine is indicated as a single agent (Ribomustin[®]) to be used in monotherapy or in combination with other anti-cancer agents for NHL, MM, and CLL in Germany. Cephalon, Inc. received US FDA Approval for TREANDA[®] to treat Patients with CLL and Relapsed Indolent NHL in March and October of 2008, respectively. Bendamustine is now under review by EMEA for NHL, MM and CLL in 13 EU countries, with granting of market authorizations expected in 2009.

Symbio Pharmaceuticals Ltd. holds exclusive rights from Astellas Deutschland GmbH to develop and market bendamustine HCl in Japan, China (HK), Taiwan, Korea and Singapore.

[Company Profile]

Symbio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate philosophy is "delivering hope to patients in need," and the company aims to address the unmet medical needs of patients in Japan and other Asia Pacific regions by cultivating a mutually beneficial or symbiotic relationship among physicians, scientists, investors, government, and patients in the healthcare industry.

[Contact]

SymBio Pharmaceuticals Limited.

Osamu Ogawa,

Board Director, Senior Corporate Officer,

Senior Director, Research & Development

Tel: +081(0)3 5472 1127

e-mail: Please send your inquiry through "INQUIRY" in our homepage

URL: <http://www.symbiosis.co.jp>